Patents by Inventor Shiow-Lin Pan

Shiow-Lin Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
    Patent number: 11919858
    Abstract: The invention relates to compounds of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: March 5, 2024
    Assignee: Calgent Biotechnology Co., Ltd.
    Inventors: Yun Yen, Jing-ping Liou, Shiow-lin Pan
  • Anti-EGF like domain multiple 6 (EGFL6) antibodies
    Patent number: 11578121
    Abstract: The invention relates to anti-EGF like domain multiple 6 antibody (anti-EGFL6 antibody) and cancer detection (or diagnosis) and treatment using the anti-EGFL6 antibody. The present invention creates anti-EGFL6 antibodies, particularly, a single-chain antibody fragments (scFv) and humanized antibody, which have ability in binding to EGFL6 and in inhibiting angiogenesis and cancer cell growth.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: February 14, 2023
    Assignees: Taipei Medical University, Changhua Christian Medical Foundation Changhua Christian Hospital, National Research institute of Chinese Medicine, Ministry of Health and Welfare
    Inventors: Yu-Ching Lee, Shiow-Lin Pan, Wei-Chun Huangfu, Tsui-Chin Huang, Po-Li Wei, Han-Li Huang, Chun-Chun Cheng, Cheng-Chiao Huang, Keng-Chang Tsai, Kun-Tu Yeh, Ting-Yi Sung, Fu-Ling Chang
  • Heat shock protein 90 inhibitors
    Patent number: 11479528
    Abstract: This disclosure is related to aromatic compounds of formula (I), and methods of their use in treating medical conditions associated with Heat Shock Protein-90 (HSP90), e.g., cancer. Compounds of formula (I) have the following structure: Also disclosed are pharmaceutical compositions comprising compounds of formula (I).
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: October 25, 2022
    Assignee: TAIPEI MEDICAL UNIVERSITY
    Inventors: Jing-ping Liou, Che-ming Teng, Shiow-lin Pan
  • Histone deacetylase 6 inhibitors and use thereof
    Patent number: 11427544
    Abstract: Disclosed is hydroxamic acid compounds of Formula (I) set forth herein. Also disclosed are a pharmaceutical composition containing such a compound and a method of using the compound for treating a condition associated with histone deacetylase 6.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: August 30, 2022
    Assignees: TAIPEI MEDICAL UNIVERSITY, NATIONAL TAIWAN UNIVERSITY
    Inventors: Che-Ming Teng, Jing-Ping Liou, Shiow-Lin Pan, Chia-Ron Yang
  • HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN
    Publication number: 20220251043
    Abstract: Disclosed herein are hydroxamic acid compounds. Also disclosed is a method of using the hydroxamic acid compounds for treating a condition associated with histone deacetylase 6.
    Type: Application
    Filed: July 22, 2020
    Publication date: August 11, 2022
    Applicant: Taipei Medical University
    Inventors: Shiow-Lin PAN, Chia-Ron YANG, Han-Li HUANG, Huang-Ju TU, Jing-Ping LIOU
  • INDOLINE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES
    Publication number: 20220184032
    Abstract: The invention relates to the use of Indoline derivatives, and their effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
    Type: Application
    Filed: March 2, 2022
    Publication date: June 16, 2022
    Inventors: Chien Huang LIN, Jing-Ping LIOU, Shiow-Lin PAN, Che-Ming TENG
  • Indoline derivatives for treatment and/or prevention of fibrosis diseases
    Patent number: 11278523
    Abstract: The invention relates to the use of Indoline derivatives, and their effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: March 22, 2022
    Assignee: Taipei Medical University
    Inventors: Chien Huang Lin, Jing-Ping Liou, Shiow-Lin Pan, Che-Ming Teng
  • Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
    Patent number: 11084786
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: August 10, 2021
    Assignee: CALGENT BIOTECHNOLOGY CO., LTD.
    Inventors: Yun Yen, Jing-Ping Liou, Shiow-Lin Pan
  • COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM
    Publication number: 20200385344
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 10, 2020
    Inventors: Yun YEN, Jing-Ping LIOU, Shiow-Lin PAN
  • Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
    Patent number: 10745350
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
    Type: Grant
    Filed: July 30, 2016
    Date of Patent: August 18, 2020
    Assignee: Calgent Biotechnology Co., Ltd.
    Inventors: Yun Yen, Jing-ping Liou, Shiow-lin Pan
  • ANTI-EGF LIKE DOMAIN MULTIPLE 6 (EGFL6) ANTIBODIES AND THEIR APPLICATIONS IN CANCER DIAGNOSIS AND TREATMENT
    Publication number: 20200239560
    Abstract: The invention relates to anti-EGF like domain multiple 6 antibody (anti-EGFL6 antibody) and cancer detection (or diagnosis) and treatment using the anti-EGFL6 antibody. The present invention creates anti-EGFL6 antibodies, particularly, a single-chain antibody fragments (scFv) and humanized antibody, which have ability in binding to EGFL6 and in inhibiting angiogenesis and cancer cell growth.
    Type: Application
    Filed: September 28, 2018
    Publication date: July 30, 2020
    Inventors: YU-CHING LEE, SHIOW-LIN PAN, Wei-Chun HUANGFU, Tsui-Chin HUANG, Po-Li WEI, Han-Li HUANG, Chun-Chun CHENG, Cheng-Chiao HUANG, Keng-Chang TSAI, Kun-Tu YEH
  • AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES
    Publication number: 20200148643
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.
    Type: Application
    Filed: January 10, 2020
    Publication date: May 14, 2020
    Inventors: Yun YEN, Jing-ping LIOU, Shiow-lin PAN
  • Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
    Patent number: 10577328
    Abstract: The invention relates to a compound of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, multiple myeloma, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: March 3, 2020
    Assignee: Taipei Medical University
    Inventors: Yun Yen, Jing-ping Liou, Shiow-lin Pan
  • HEAT SHOCK PROTEIN 90 INHIBITORS
    Publication number: 20200039923
    Abstract: This disclosure is related to aromatic compounds of formula (I), and methods of their use in treating medical conditions associated with Heat Shock Protein-90 (HSP90), e.g., cancer. Compounds of formula (I) have the following structure: Also disclosed are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: March 20, 2018
    Publication date: February 6, 2020
    Inventors: Jing-ping LIOU, Che-ming TENG, Shiow-lin PAN
  • HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF
    Publication number: 20190284141
    Abstract: Disclosed is hydroxamic acid compounds of Formula (I) set forth herein. Also disclosed are a pharmaceutical composition containing such a compound and a method of using the compound for treating a condition associated with histone deacetylase 6.
    Type: Application
    Filed: May 16, 2017
    Publication date: September 19, 2019
    Applicant: DCB-USA LLC
    Inventors: Che-Ming TENG, Jing-Ping LIOU, Shiow-Lin PAN, Chia-Ron YANG
  • COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM
    Publication number: 20190144383
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
    Type: Application
    Filed: July 30, 2016
    Publication date: May 16, 2019
    Inventors: Yun YEN, Jing-ping LIOU, Shiow-lin PAN
  • AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES
    Publication number: 20180319749
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.
    Type: Application
    Filed: July 23, 2015
    Publication date: November 8, 2018
    Inventors: Yun YEN, Jing-ping LIOU, Shiow-lin PAN
  • 20()-sulfonylamidine derivatives of camptothecin and the use thereof as a potent antitumor agent
    Patent number: 9718835
    Abstract: The present invention is related to novel 20-sulfonylamidine derivatives of camptothecin (1), method of synthesizing the same, and use thereof as an antitumor agent, for examples an antitumor agent for treating nasopharyngeal, lung, breast or prostate cancer.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: August 1, 2017
    Assignees: CHINA MEDICAL UNIVERSITY HOSPITAL, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Kuo-Hsiung Lee, Keduo Qian, Xiaoming Yang, Masuo Goto, Ying-Qian Liu, Yong-Long Zhao, Liu Yang, Mei-Juan Wang, Zhi-Jun Zhang, Tian-Shung Wu, Che-Ming Teng, Chih-Ya Wang, Shiow-Lin Pan, Sheng-Chu Kuo, Hsin-Yi Hung, Ling-Chu Chang, Yang-Chang Wu, Min-Tsang Hsieh, Chung Y. Hsu, Woei-Cherng Shyu, Chen-Huan Lin
  • NOVEL 20(S)-SULFONYLAMIDINE DERIVATIVES OF CAMPTOTHECIN AND THE USE THEREOF AS A POTENT ANTITUMOR AGENT
    Publication number: 20160229862
    Abstract: The present invention is related to novel 20-sulfonylamidine derivatives of camptothecin (1), method of synthesizing the same, and use thereof as an antitumor agent, for examples an antitumor agent for treating nasopharyngeal, lung, breast or prostate cancer.
    Type: Application
    Filed: September 26, 2014
    Publication date: August 11, 2016
    Inventors: Kuo-Hsiung LEE, Keduo QIAN, Xiaoming YANG, Masuo GOTO, Ying-Qian LIU, Yong-Long ZHAO, Liu YANG, Mei-Juan WANG, Zhi-Jun ZHANG, Tian-Shung WU, Che-Ming TENG, Chih-Ya WANG, Shiow-Lin PAN, Sheng-Chu KUO, Hsin-Yi HUNG, Ling-Chu CHANG, Yang-Chang WU, Min-Tsang HSIEH, Chung Y. HSU, Woei-Cherng SHYU, Chen-Huan LIN
  • INDOLINE COMPOUNDS FOR TREATMENT AND/OR PREVENTION OF INFLAMMATION DISEASES
    Publication number: 20150368195
    Abstract: The invention is based on the discovery that 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines and 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles has great potential as a novel agent to be used in the treatment of inflammation-associated diseases, particularly, inflammatory arthritis and fibrosis.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 24, 2015
    Inventors: Jing-Ping Liou, Chien-Huang Lin, Shiow-Lin Pan, Chia-Ron Yang, Che-Ming Teng